Regulation of insulin-like growth factors and their binding proteins by thyroid stimulating hormone in human osteoblast-like (SaOS2) cells

详细信息    查看全文

• 作者：G. Ramajayam (1)
  R. C. Vignesh (1)
  S. Karthikeyan (1)
  K. Senthil Kumar (1)
  G. D. Karthikeyan (1)
  S. Veni (1)
  M. Sridhar (2)
  J. Arunakaran (1)
  M. Michael Aruldhas (1)
  N. Srinivasan (1) n_srini2000@yahoo.com
• 关键词：IGF – ; TSH – ; IGFBP – ; SaOS2 – ; PAPP ; A
• 刊名：Molecular and Cellular Biochemistry
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：368
• 期：1-2
• 页码：77-88
• 全文大小：514.1 KB
• 参考文献：1. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M (2003) TSH is a negative regulator of skeletal remodeling. Cell 115:151–162
  2. Peeters RP, van der Deure WM, Visser TJ (2006) Genetic variation in thyroid hormonepathway genes: polymorphisms in the TSH receptor and the iodothyronine deiodinases. Eur J Endocrinol 155:655–662
  3. Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O’Brien S, Schiavi SC, McPherson JM, Vukicevic S (2007) Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res 22:849–859
  4. Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, McPherson J, Zhu LL, Iqbal J, Latif R, Natrajan A, Arabi A, Yamoah K, Moonga BS, Gabet Y, Davies TF, Bab I, Abe E, Sampath K, Zaidi M (2008) Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci USA 11:4289–4294
  5. van der Deure WM, Uitterlinden AG, Hofman A, Rivadeneira F, Pols HA, Peeters RP et al (2008) Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol 68:175–181
  6. Iida K, Hino Y, Ohara T, Chihara K (2011) A case of myxedema coma caused by isolated thyrotropin stimulating hormone deficiency and Hashimoto’s thyroiditis. Endocr J 58:143–148
  7. Ma R, Morshed S, Latif R, Zaidi M, Davies TF (2011) The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on. Thyroid 21:897–906
  8. Hase H, Ando T, Eldeiry L, Brebene A, Peng Y, Liu L, Amano H, Davies TF, Sun L, Zaidi M, Abe E (2006) TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci USA 103:12849–12854
  9. Canalis E (1994) Skeletal growth factors and aging. J Clin Endocrinol Metab 78:1009–1010
  10. Mohan S, Baylink DJ (1999) IGF system components and their role in bone metabolism. In: Rosenfeld RG, Roberst C (eds) IGFs in health and disease. Humana Press, New York, pp 457–496
  11. Mohan S, Baylink DJ (1991) Bone growth factors. Clin Orthop 263:30–48
  12. Canalis E (1997) Insulin-like growth factors and osteoporosis. Bone 21:215–216
  13. Gray TK, Mohan S, Linkhart TA, Baylink DJ (1989) Estradiol stimulates in vitro the secretion of insulin-like growth factors by the clonal osteoblastic cell line, UMR106. Biochem Biophys Res Commun 158:407–412
  14. McCarthy TL, Centrella M, Canalis E (1989) Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 124:1247–1253
  15. Lakatos P, Caplice MD, Khanna V, Stern PH (1993) Thyroid hormones increase insulin-like growth factor-I content in the medium of rat bone tissue. J Bone Miner Res 8:1475–1481
  16. Varga F, Rumpler M, Klaushofer K (1994) Thyroid hormones increase insulin-like growth factor mRNA levels in the clonal osteoblastic cell line MC3T3-E1. FEBS Lett 345:67–70
  17. Chen TL, Mallory MB, Hintz RL (1991) Dexamethasone and 1,25(OH)2 vitamin D3 modulate the synthesis of insulin-like growth factor-I in osteoblast-like cells. Calcif Tissue Int 48:278–282
  18. Canalis E (1996) Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. Review. J Clin Endocrinol Metab 81:3441–3447
  19. Cheng S-L, Yang JW, Rifas L, Zhang S-F, Avioli LV (1994) Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. Endocrinology 134:277–286
  20. Canalis E, Gabbitas B (1995) Skeletal growth factors regulate the synthesis of insulin-like growth factor binding protein-5 in bone cell cultures. J Biol Chem 270:10771–10776
  21. Schmid C, Schlapfer I, Futo E, Waldvogel M, Schwander J, Zapf J, Froesch ER (1992) Triiodothyronine (T3) stimulates insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-2 production by rat osteoblasts in vitro. Acta Endocrinol 126:467–473
  22. Nakao Y, Hilliker S, Baylink DJ, Mohan S (1994) Studies on the regulation of insulin-like growth factor binding protein 3 secretion in human osteosarcoma cells in vitro. J Bone Miner Res 9:865–872
  23. Srinivasan N, Baylink DJ, Sampath K, Mohan S (1997) Effects of inhibitors of signal transduction pathways on transforming growth factor-beta 1 and osteogenic protein-1-induced insulin-like growth factor binding protein-3 expression in human bone cells. J Cell Physiol 173:28–35
  24. Ueland T, Bollerslev J, Hansen TB, Ebbesen EN, Mosekilde L, Brixen K (1999) Increased cortical bone content of insulin-like growth factors in acromegalic patients. J Clin Endocrinol Metab 84:123–127
  25. Erclik MS, Mitchell J (2005) Activation of the insulin-like growth factor binding protein-5 promoter by parathyroid hormone in osteosarcoma cells requires activation of an activated protein-2 element. J Mol Endocrinol 34:713–722
  26. Gabbitas B, Canalis E (1998) Insulin-like growth factors sustain insulin-like growth factor-binding protein-5 expression in osteoblasts. Am J Physiol 275:222–228
  27. Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C et al (1995) lStudies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 270:20424–20431
  28. Mukherjee A, Rotwein P (2008) Insulin-like growth factor-binding protein-5 inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth factor actions. Mol Endocrinol 22:1238–1250
  29. Backeljauw PF, Dai Z, Clemmons DR, D’Ercole AJ (1993) Synthesis and regulation of insulin-like growth factor binding protein-5 in FRTL-5 cells. Endocrinology 132:1677–1681
  30. Kudo Y, Iwashita M, Iguchi T, Takeda Y, Hizuka N, Takano K, Muraki T (1997) Estrogen and parathyroid hormone regulate insulin-like growth factor binding protein-4 in SaOS-2 cells. Life Sci 61:165–170
  31. Kveiborg M, Flyvbjerg A, Eriksen EF, Kassem M (2001) 1,25-Dihydroxyvitamin D3 stimulates the production of insulin-like growth factor-binding proteins-2, -3 and -4 in human bone marrow stromal cells. Eur J Endocrinol 144:549–557
  32. Strohbach C, Kleinman S, Linkhart T, Amaar Y, Chen ST, Mohan S, Strong D (2008) Potential involvement of the interaction between insulin-like growth factor binding protein (IGFBP)-6 and LIM mineralization protein (LMP)-1 in regulating osteoblast differentiation. J Cell Biochem 104:1890–1905
  33. Zhao YY, Guo L, Zhao XJ, Liu H, Lei T, Ma DJ, Gao XY (2009) Transcriptional activation of insulin-like growth factor binding protein 6 by 17beta-estradiol in SaOS-2 cells. Exp Mol Med 41:478–486
  34. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR, Conover CA (1999) The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci 96:3149–3153
  35. Kudo Y, Iwashita M, Iguchi T, Takeda Y, Hizuka N, Takano K, Muraki T (1997) Estrogen and parathyroid hormone regulate insulin-like growth factor binding protein-4 in SaOS-2 cells. Life Sci 61:165–170
  36. Ortiz CO, Chen BK, Bale LK, Overgaard MT, Oxvig C, Conover CA (2003) Transforming growth factor-beta regulation of the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts. J Bone Miner Res 18:1066–1072
  37. Matsumoto T, Gargosky SE, Kelley K, Rosenfeld RG (1996) Characterization of an insulin-like growth factor binding protein-5 protease produced by rat articular chondrocytes and a neuroblastoma cell line. Growth Regul 6:185–190
  38. Morgan SJ, Darling DC (1993) Animal cell culture. BIOS Scientific in Association with the Biochemical Society, London
  39. Andersch MA, Szczypinski AJ (1947) Use of p-nitrophenylphosphate as the substrate in determination of serum acid phosphatase. Am J Clin Pathol 17:571–574
  40. Sila-Asna M, Bunyaratvej A, Maeda S, Kitaguchi H, Bunyaratavej N (2007) Osteoblast differentiation and bone formation gene expression in strontiuminducing bone marrow mesenchymal stem cell. Kobe J Med Sci 53:25–35
  41. Lowry OH, Rosebrough NJ, Farr AB, Randall RJ (1951) Protein measurement with folin phenol reagent. J Biol Chem 193:265–275
  42. Inoue M, Tawata M, Yokomori N, Endo T, Onaya T (1998) Expression of thryotropin receptor on clonal osteoblast-like rat osteosarcoma cells. Thyroid 8:1059–1064
  43. Tsai JA, Janson A, Bucht E, Kindmark H, Marcus C, Stark A, Zemack HR, Torring O (2004) Weak evidence of thyrotropin receptors in primary cultures of human osteoblast-like cells. Calcif Tissue Int 74:486–491
  44. Tramontano D, Moses AC, Ingbar SH (1988) The role of adenosine 3′,5′-monophosphate in the regulation of receptors for thyrotropin and insulin-like growth factor I in the FRTL5 rat thyroid follicular cell. Endocrinology 122:133–136
  45. Baliram R, Latif R, Berkowitz J, Frid S, Colaianni G, Sun L, Zaidi M, Davies TF (2011) Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures. Proc Natl Acad Sci USA 108:16277–16282
  46. Billiard J, Grewal SS, Lukaesko L, Stork PJ, Rotwein P (2001) Hormonal control of insulin-like growth factor I gene transcription in human osteoblasts: dual actions of cAMP-dependent protein kinase on CCAAT/enhancer-binding protein delta. J Biol Chem 76:31238–31246
  47. Morimura T, Tsunekawa K, Kasahara T, Seki K, Ogiwara T, Mori M, Murakami M (2005) Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 146:2077–2084
  48. Phillips ID, Becks GP, Wang JF, Han VK, Hill DJ (1994) Hormonal regulation and biological actions of insulin-like growth factor binding proteins in isolated ovine thyroid follicles. Endocrinology 1994(134):1238–1246
  49. Imagawa M, Chiu R, Karin M (1987) Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 51:251–260
  50. Rivas M, Santisteban P (2003) TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 213:31–45
  51. Duan C, Liimatta MB, Bottum OL (1999) Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway. J Biol Chem 274:37147–37153
  52. Tanno B, Negroni A, Vitali R, Pirozzoli MC, Cesi V, Mancini C, Calabretta B, Raschell脿 G (2002) Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms. J Biol Chem 277:23172–23180
  53. Zaballos MA, Garcia B, Santisteban P (2008) Gbetagamma dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells. Mol Endocrinol 22:1183–1199
  54. Choi HS, Lee JH, Park JG, Lee YI (2002) Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex. Biochem Biophys Res Commun 296:1005–1012
  55. Fanelli A, Grollman EF, Wang D, Philp NJ (2003) MCT1 and its accessory protein CD147 are differentially regulated by TSH in rat thyroid cells. Am J Physiol Endocrinol Metab 285:1223–1229
  56. Wang E, Wang J, Chin E, Zhou J, Boundy CA (1995) Cellular patterns of insulin-like growth factor system gene expression in murine chondrogenesis and osteogenesis. Endocrinology 136:2741–2751
  57. Laursen LS, Overgaard MT, Soe R, Boldt HB, Sottrup-Jensen L, Giudice LC, Conover CA, Oxvig C (2001) Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin- like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 504:36–40
  58. Clemmons DR (1997) Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8:45–62
  59. Marinaro JA, Neumann GM, Russo VC, Leeding KS, Bach LA (2000) O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis. Eur J Biochem 267:5378–5386
  60. Song BL, Qi W, Yang XY, Chang CC, Zhu JQ, Chang TY, Li BL (2001) Organization of human ACAT-2 gene and its cell-type-specific promoter activity. Biochem Biophys Res Commun 282:580–588
  61. Guo L, Zhao YY, Zhao YY, Sun ZJ, Liu H, Zhang SL (2007) Toxic effects of TCDD on osteogenesis through altering IGFBP-6 gene expression in osteoblasts. Biol Pharm Bull 30:2018–2026
  62. Maor G, Segev Y, Phillip M (1999) Testosterone stimulates insulin-like growth factor-I and insulin-like growth factor-I-receptor gene expression in the mandibular condyle—a model of endochondral ossification. Endocrinology 140:1901–1910
  63. Bassett JH, Harvey CB, Williams GR (2003) Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 213:1–11
  64. Conover CA, Bale LK, Clarkson JT, T酶rring O (1993) Regulation of insulin-like growth factor binding protein-5 messenger ribonucleic acid expression and protein availability in rat osteoblast-like cells. Endocrinology 132:2525–2530
  65. Zhang W, Deng ZL, Chen L, Zuo GW, Luo Q, Shi Q, Zhang BQ, Wagner ER, Rastegar F, Kim SH, Jiang W, Shen J, Huang E, Gao Y, Gao JL, Zhou JZ, Luo J, Huang J, Luo X, Bi Y, Su Y, Yang K, Liu H, Luu HH, Haydon RC, He TC, He BC (2010) Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. PLoS ONE 5:e11917
  66. Scharla SH, Strong DD, Rosen C, Mohan S, Holick M, Baylink DJ, Linkhart TA (1993) 1,25-Dihydroxyvitamin D3 increases secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in vivo. J Clin Endocrinol Metab 77:1190–1197
  67. Chevalley T, Strong DD, Mohan S, Baylink D, Linkhart TA (1996) Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation. Eur J Endocrinol 134:591–601
  68. Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C (2005) Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 20:480–486
• 作者单位：1. Department of Endocrinology, Dr. ALMPGIBMS, University of Madras, Chennai, 600 113 India2. Department of Radiation Oncology, College of Medicine, Chungbuk National University, Cheongju, 361-763 South Korea
• ISSN：1573-4919

文摘

Thyroid stimulating hormone (TSH) is shown to have definite anabolic effects on skeletal metabolism. Previous studies have demonstrated that Insulin-like growth factors (IGF-I and IGF-II) and their six high affinity binding proteins (IGFBPs 1–6) regulate proliferation and differentiation of bone-forming osteoblasts. The current study was intended to determine whether the anabolic effects of TSH on human osteoblastic (SaOS2) cells are mediated through insulin-like growth factor system components. TSH given at 0.01 ng to 10 ng/ml dose levels for 24 and 48 h significantly increased human osteoblastic (SaOS2) cell proliferation and alkaline phosphatase activity, the differentiation marker. TSH significantly increased IGFs (IGF-I and IGF-II) mRNA expression after 6 and 24 h and their protein levels after 24 and 48 h of treatment, respectively. Unlike the IGFs, the IGFBPs responded differently to TSH treatment. Though there were some inconsistencies in the regulation of stimulatory IGF binding protein-3 and -5 by TSH treatment, there was an overall increase at the mRNA abundance and protein levels. Again, the inconsistency persisted at the regulation of the inhibitory IGFBPs 2, 4, and 6 especially at the level of mRNA expression due to TSH treatment, there is an overall decrease in the levels of IGFBP-2, 4, and 6 in the conditioned media (CM) of SaOS2 cell cultures. The IGFBP proteases which control the availability of IGFs are also regulated by hormones. Pregnancy-Associated Plasma Protein-A (PAPP-A) is responsible for the proteolysis of IGFBP-4. TSH treatment significantly unregulated the expression of PAPP-A both at mRNA and protein levels. In conclusion, TSH promotes human osteoblastic (SaOS2) cell proliferation and differentiation by upregulating IGFs and their stimulatory IGF binding proteins and down regulating the inhibitory IGF binding proteins.